hC Bioscience completed the acquisition of 4SR Biosciences.

hC Bioscience, a company in the development of tRNA-based therapeutic, completed the acquisition of 4SR Biosciences, a University of Chicago startup focusing on tRNA diagnostics and therapeutics. Financial terms were not disclosed. “This deal consolidates proprietary discovery platforms, IP, and scientific expertise that will greatly advance our ability to discover and develop tRNA-based therapies. Bringing their powerful research tools and expertise in tRNA and structural biology in-house enables us to better understand fundamental mechanisms of tRNA biology and disease pathways associated with genetic errors and, importantly, how best to intervene with engineered tRNAs. We are excited for Drs Katanski and McGilvray to join us to advance tRNA as a therapeutic modality and for Dr. Pan, a leading authority and pioneer in the tRNA field, to join our Scientific Advisory Board,” Leslie Williams, hC Bioscience CEO.